GSK and Eli Lilly are the latest multinational drugmakers to unveil plans to build more U.S. manufacturing plants and other operations, moves aimed partly at mitigating the threat of tariffs

Core Insights - GSK and Eli Lilly are expanding their manufacturing and operational capabilities in the United States [1] Group 1 - GSK has announced plans to enhance its manufacturing operations in America [1] - Eli Lilly is also set to increase its operational footprint in the U.S. [1]